Reactivation of the Human Herpes Virus 6 in Kidney Transplant Recipients : An Unsolved Question by S. Delbue et al.
Reactivation of the Human Herpes Virus 6 in Kidney Transplant Recipients: An
Unsolved Question
Serena Delbue1, Ramona Bella1 and Mariano Ferraresso2,3*
1Department of Biomedical, Surgery and Dental Sciences, University of Milano, Italy
2Department of Clinical Sciences and Community Health, University of Milano, Italy
3Division of Kidney Transplantation, Ca’Granda Foundation, I.R.C.C.S,Milan, Italy
*Corresponding author: Mariano Ferraresso, Department of Clinical Sciences and Community Health, Via F. Sforza 12, 20122 Milan, Italy, Tel: +39 0250320382; Fax:
+39 0250320393; E-mail: mariano.ferraresso@unimi.it
Rec date: Feb 05, 2015, Acc date: Feb 09, 2015, Pub date: Feb 11, 2015
Copyright: © 2015 Delbue S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Editorial
Human herpesvirus 6A (HHV6A) and human herpesvirus 6B
(HHV6B) belong to the Roseolovirus genus, within the order
Herpesvirales, family Herpesviridae and subfamily Betaherpesvirales.
HHV6 infection is ubiquitous in the world population and the virus
is able to establish a lifelong latency mainly in the peripheral blood
monocytes (PBMC), after the primary infection that usually occurs
during the early childhood.
The HHV6 reactivation is closely related to the host's
immunological status, and consequently the immunocompromised
subjects, such as the organ recipients are at high risk of experiencing
viral reactivation, that can result in some complications after
transplantation, up to the graft rejection.
The HHV6 replication in the kidney transplant patients range
between 0% and 80%, but only in about 1% of the cases it is associated
with the clinical symptoms.
The scientific scenario of the HHV6 implication in the development
of post-transplant disorders still presents some controversial issues,
that deserve many other in depth analysis, both epidemiological and
molecular, in order to be solved.
In 1986, HHV6 was firstly isolated from the Peripheral Blood
Mononuclear Cells (PBMC) of HIV positive patients affected with
lymphoproliferative disorders, and for this reason it was initially
identified as Human B- Lymphotrofic Virus (HBLV) [1]. The viral
particle has variable size, ranging between 160 and 200 nm in
diameter, and consisting of four main components: core, capsid,
tegument and envelope [2].
The genome is composed by a double-stranded, linear, 161571 bp
long DNA molecule, consisting of a single region (U) of 145 kb flanked
by direct terminal repeats, DRL e DRR, of 8-9 kb and interrupted by
three intermediate repeats, R1, R2 and R3. In the central portion of the
genome there are conserved genes among α, β and γ herpesvirus,
which encode for the structural components of the virion and for the
enzymes involved in viral replication [3].
In 1992, two variants of HHV6 were identified on the base of
different molecular, epidemiological, and immunological features, and
were named HHV6A and HHV6B. Only twenty years after, in 2012,
the International Committee on Taxonomy of Viruses (ICTV) decided
to classify the two variants as separate and distinct viruses [4].
As for the other betaherpesviruses, HHV6 is considered an
ubiquitous virus and its worldwide seroprevalence is now approaching
100%, with the exception of Morocco, where only 20% of individuals
are found to have anti HHV6 antibodies.
In USA, UK and Japan, HHV6B is recognized to be the causative
agent of the roseola infantum (exanthema subitum), which is a febrile
illness associated with skin rash, characterized by an incubation period
of about two weeks, common during early childhood. The main
features of this infectious disease may be several days of high fever and
upper respiratory illness, followed by a pinkish-red flat or raised rash
on the trunk and spreads to the neck, face, arms, and legs in about 20%
of young children or by febrile seizures in about 10-15% of infected
children. Rarely complications such as seizures, otitis, respiratory or
gastrointestinal symptoms, encephalitis and hepatitis have been
described [5,6].
On the contrary, no symptomatic infections have been described for
the HHV6A, except in Sub Saharian Africa, where it causes viremic
infection and febrile disease in the pediatric population; nevertheless
the presence of HHV6A, that seems to have strong neurotropism, has
been associated with the pathogenesis of several neurological diseases,
such as Multiple Sclerosis (MS) [4,7,8]. After the primary infection,
HHV6 establishes latency in the host, maintaining the genome in an
episomal state, replicating at very low level, mainly in PBMCs, and in
the salivary glands [9], but also in the oligodendrocytes and in the
bone marrow progenitor cells. In a minority of the cases, the virus is
able to integrate its genome in the human chromosomes by
homologous recombination in a similar way to the avian virus, that
causes Marek's disease, which is integrated in the host telomeres [10].
This condition is known as “chromosomally integrated HHV6
(CIHHV-6), and it is very important since in these cases, HHV6
infection may be inherited [11].
HHV6 infection is frequently detected in immunosuppressed
transplant patients, as result of reactivation of a latent virus more than
as result of a primary infection, that is very uncommon during the
adulthood. The rates of HHV6 reactivation range within 38-60%
among the bone marrow transplant recipients and between 31-55%
among solid organ transplant recipients; generally viral reactivation
occurs after 3 months from transplantation. HHV6 replication in
transplant recipients is usually asymptomatic, even if sometimes (about
1% of the cases) it can be associated with pneumonia, encephalitis,
fever, skin rash, transplant rejection [12,13].
Focusing on kidney transplants, several studies reported conflicting
results about reactivation of HHV6 both in pediatric and adult
patients. The percentage of presence of the HHV6 genome ranges from
0 to 80%, and these differences are strongly influenced by the age
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population, and the techniques employed for the DNA detection.
Additionally, HHV6B reactivates more often than HHV6A, but the
replication of HHV6A is more virulent [14] and can also be fatal
[15,16].
HHV6 has been also associated with a higher risk of Human
Cytomegalovirus (HCMV) disease, and concomitant or recent HCMV
infection may induce strong clinical symptoms [17].
Our study has been conducting on pediatric and young adult kidney
transplant recipients, with the main aim to assess the presence, and the
rate of replication of HHV6A and B in blood samples. To date, the very
preliminary data showed that the virus genome is present in about 21%
of the 77 patients, without any association among the presence of the
genome, the patients’ age, the time passed from the transplant or the
HCMV coinfection. The mean viral load was 788.5 copies/mL, ranging
61-1800 copies/mL, and interestingly, the HHV-6A was detected more
frequently than the HHV-6B. So far, the HHV6 positive patients did
not show any clinical symptoms (unpublished data).
In conclusion HHV6 is an emerging pathogen that may be
associated to some post-transplants disorders, similarly to those
caused by HCMV [7,18], but the scenario still presents some unsolved
issues. In particular, the ubiquity of the infection, and the latency of
the virus, often in an asymptomatic form, the controversial significance
of CIHHV6 and its potential reactivation in immunosuppresion
setting, the difficulties in performing the diagnosis are some of the
questions that still need to be addressed. Many other epidemiological
and functional studies are consequently needed, with the final aim to
conduct a correct management of the state of immunosuppression
associated with organ transplantation, implement adequate
prophylaxis in kidney transplant recipients, prevent the onset of other
opportunistic infections and severe pathological manifestations.
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